ADVAIR DISKUS 100/50
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADVAIR DISKUS 100/50 (ADVAIR DISKUS 100/50).
Fluticasone propionate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, thereby inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production. Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, increasing cAMP levels, leading to bronchodilation and inhibition of mast cell mediator release.
| Metabolism | Fluticasone propionate undergoes extensive first-pass metabolism via cytochrome P450 3A4 (CYP3A4) to an inactive carboxylic acid metabolite. Salmeterol is metabolized primarily by CYP3A4 to alpha-hydroxysalmeterol. |
| Excretion | Fluticasone propionate: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (~5% unchanged), fecal elimination of parent drug and metabolites. Salmeterol: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (about 25% of dose), fecal elimination. |
| Half-life | Fluticasone propionate: terminal half-life approximately 8 hours (range 4-12 hours) after inhalation; clinical context: supports twice-daily dosing. Salmeterol: terminal half-life approximately 5.5 hours (range 3-10 hours) after inhalation; clinical context: supports twice-daily dosing. |
| Protein binding | Fluticasone propionate: approximately 90% bound to plasma proteins (primarily albumin). Salmeterol: approximately 96% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | Fluticasone propionate: Vd approximately 4.2 L/kg (range 3-6 L/kg), indicating extensive tissue distribution. Salmeterol: Vd approximately 7 L/kg (range 5-10 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Fluticasone propionate: absolute bioavailability from inhaled ADVAIR DISKUS is approximately 18% (range 15-21%), due to lung deposition and low oral bioavailability (<1%). Salmeterol: absolute bioavailability from inhaled ADVAIR DISKUS is approximately 25% (range 20-30%), due to lung deposition; oral bioavailability is negligible. |
| Onset of Action | Fluticasone propionate: clinical effect on asthma symptoms may be seen within 1-2 days, maximum benefit after 1-2 weeks. Salmeterol: bronchodilation begins within 10-20 minutes after inhalation; peak effect at 2-4 hours. |
| Duration of Action | Fluticasone propionate: anti-inflammatory effect persists for 12 hours; twice-daily dosing required. Salmeterol: bronchodilation lasting 12 hours; twice-daily dosing appropriate, not for acute symptom relief. |
| Molecular Weight | Fluticasone propionate: 500.57 Da; Salmeterol: 415.6 Da (as xinafoate salt 603.8 Da) |
| Action Class | Corticosteroid/LABA Combination |
One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart, via oral inhalation.
| Dosage form | POWDER |
| Renal impairment | No dosage adjustment required for renal impairment; pharmacokinetics not significantly altered. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B and C: Use with caution; consider reduced dose due to increased systemic exposure; monitor for adverse effects. |
| Pediatric use | Not recommended for children under 12 years. For adolescents 12 years and older, same as adult dosing: 1 inhalation twice daily. |
| Geriatric use | No specific dose adjustment; use lowest effective dose; monitor for systemic corticosteroid effects and cardiovascular events due to salmeterol. |
| 1st trimester | Insufficient human data; animal studies show no teratogenic effects at inhaled doses. Use only if benefit outweighs risk. |
| 2nd trimester | Monitor for fetal growth restriction due to maternal asthma exacerbation; consider lowest effective dose. |
| 3rd trimester | Use with caution; may cause fetal bradycardia and hypoglycemia from beta-agonist component; monitor neonatal blood glucose and heart rate. |
Clinical note
Comprehensive clinical and safety monograph for ADVAIR DISKUS 100/50 (ADVAIR DISKUS 100/50).
| Placental transfer | Limited data; both components cross placenta in animals. In humans, fluticasone propionate has low systemic bioavailability; salmeterol crosses placenta in animal studies. |
| Breastfeeding | Fluticasone propionate and salmeterol are excreted in human milk in small amounts. Exercise caution and use only if clearly needed. Monitor infant for signs of beta-agonist exposure (tachycardia, agitation). |
■ FDA Black Box Warning
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Therefore, ADVAIR DISKUS 100/50 should only be used for asthma in patients not adequately controlled on a long-term asthma control medication (e.g., inhaled corticosteroid) or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
| Common Effects | Upper respiratory tract infection, Throat irritation, Hoarseness/dysphonia, Oral candidiasis (thrush), Headache, Musculoskeletal pain, Nausea and vomiting, Cough, Sinusitis, Pharyngitis |
| Serious Effects | Increased risk of asthma-related death (LABA component), Adrenal insufficiency, Serious allergic reactions (anaphylaxis, angioedema), Cardiovascular effects (tachycardia, arrhythmias, hypertension), Hypokalemia, Hyperglycemia, Osteoporosis with long-term use, Glaucoma and cataracts, Growth suppression in children, Eosinophilic conditions (Churg-Strauss syndrome) |
Hypersensitivity to any componentStatus asthmaticus or acute asthma exacerbation requiring intensive careSevere hypersensitivity to milk proteins (lactose monohydrate contains trace milk proteins)
| Precautions |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. Fluticasone propionate and salmeterol: No adequate human studies. In animal studies, fluticasone caused fetal toxicity at high doses (cleft palate, reduced fetal weight) at doses ≥30 mcg/kg SC; salmeterol caused delayed ossification and reduced survival at doses ≥1.4 mg/kg PO. First trimester: No data for ADVAIR; avoid unless benefit outweighs risk. Second/third trimester: Use only if clearly needed; monitor fetal growth and consider risk of maternal asthma exacerbation. |
| Fetal Monitoring | Monitor maternal asthma symptoms, peak flow, FEV1. Assess fetal growth via ultrasound if prolonged use. Monitor for maternal corticosteroid side effects (hyperglycemia, bone density) in long-term use. No specific fetal monitoring required unless preeclampsia or growth restriction develops. |
| Fertility Effects | No human data on fertility. In animal studies, high-dose fluticasone (≥50 mcg/kg SC) caused prolonged estrous cycle and reduced fertility; salmeterol (≥1.4 mg/kg PO) had no fertility effects. Clinical significance unknown. Asthma control may improve fertility outcomes. |
| Increased risk of asthma-related death with LABA use, Cardiovascular effects (e.g., increased blood pressure, tachycardia, arrhythmias), Paradoxical bronchospasm, Hypersensitivity reactions (e.g., anaphylaxis, angioedema), Hypercorticism and adrenal suppression with high doses or prolonged use, Reduced bone mineral density with long-term use, Pneumonia risk in COPD patients, Ketoacidosis in patients with diabetes |
| Food/Dietary | No specific food interactions; avoid grapefruit juice as it may increase fluticasone systemic absorption. Take with or without food. |
| Clinical Pearls | ADVAIR DISKUS 100/50 (fluticasone propionate 100 mcg/salmeterol 50 mcg) is a combination inhaler for maintenance therapy of asthma or COPD; not for acute bronchospasm. Rinse mouth after use to prevent oral candidiasis. Monitor for increased blood pressure, tachycardia, and hypokalemia due to salmeterol. Do not use as monotherapy in asthma without inhaled corticosteroid; salmeterol increases risk of asthma-related death when used alone. Diskus device delivers medication via a breath-activated dry powder; ensure patient breaths in rapidly and deeply. |
| Patient Advice | Use exactly as prescribed; do not use more puffs than directed. · Rinse mouth with water after each use (do not swallow) to prevent thrush. · Do not use for sudden breathing problems; have a rescue inhaler (e.g., albuterol) available. · If you miss a dose, skip it; do not double the dose. · Call your doctor if symptoms worsen or you need more rescue inhaler than usual. · Store diskus at room temperature away from moisture and heat; keep closed when not in use. · Do not stop taking this medicine without consulting your doctor. |